Buy Pfizer; target of Rs 5890: ICICI Direct

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

ICICI Direct's research report on Pfizer

Q2FY21 revenues grew 5% YoY to Rs 595 crore. Adjusting for divesture of rights & interests in certain brands and Covid-19, YoY growth for the quarter was at 10.1%. Also, hospital and vaccines business reflected improved performance due to easing of lockdown. EBITDA margins expanded 520 bps to 34.1% YoY due to a better overall operational performance. Decline in other expenses is likely on account of lower promotional & marketing activities. Hence, EBITDA grew 23.8% YoY to Rs 203 crore. However, PAT de-grew 14.8% YoY to Rs 131 crore. Delta vis-à-vis EBITDA was due to lower other income, higher tax rate (28.2% vs. 14.9% in Q2FY20).

Outlook

We maintain BUY recommendation and arrive at a target price of Rs 5890 based on 40x FY22 EPS of Rs 147.3.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More